600216 浙江医药
已收盘 12-17 15:00:00
资讯
新帖
简况
浙江医药（600216）发布向2025年限制性股票激励计划激励对象授予限制性股票公告，11月26日股价上涨0.14%
证券之星 · 11-26
浙江医药（600216）发布向2025年限制性股票激励计划激励对象授予限制性股票公告，11月26日股价上涨0.14%
浙江医药(600216.SH)筹划分拆控股子公司新码生物于香港联交所上市
智通财经 · 11-26
浙江医药(600216.SH)筹划分拆控股子公司新码生物于香港联交所上市
每周股票复盘：浙江医药（600216）推1.07%股本激励计划
证券之星 · 11-16
每周股票复盘：浙江医药（600216）推1.07%股本激励计划
浙江医药（600216）发布2025年限制性股票激励计划，11月13日股价上涨0.27%
证券之星 · 11-13
浙江医药（600216）发布2025年限制性股票激励计划，11月13日股价上涨0.27%
每周股票复盘：浙江医药（600216）拟授1028.4万股限制性股票
证券之星 · 11-09
每周股票复盘：浙江医药（600216）拟授1028.4万股限制性股票
浙江医药（600216）披露2025年限制性股票激励计划激励对象名单公示结果，11月07日股价上涨1.91%
证券之星 · 11-07
浙江医药（600216）披露2025年限制性股票激励计划激励对象名单公示结果，11月07日股价上涨1.91%
浙江医药（600216）披露拟实施2025年限制性股票激励计划，11月05日股价下跌0.34%
证券之星 · 11-05
浙江医药（600216）披露拟实施2025年限制性股票激励计划，11月05日股价下跌0.34%
每周股票复盘：浙江医药（600216）Q3净利降51.37%，推1028.4万股激励计划
证券之星 · 11-02
每周股票复盘：浙江医药（600216）Q3净利降51.37%，推1028.4万股激励计划
浙江医药（600216）披露2025年限制性股票激励计划（草案），10月28日股价上涨0.49%
证券之星 · 10-28
浙江医药（600216）披露2025年限制性股票激励计划（草案），10月28日股价上涨0.49%
图解浙江医药三季报：第三季度单季净利润同比下降51.37%
证券之星 · 10-28
图解浙江医药三季报：第三季度单季净利润同比下降51.37%
浙江医药最新公告：拟投资16.85亿元建设昌北生物建设项目
证券之星 · 10-27
浙江医药最新公告：拟投资16.85亿元建设昌北生物建设项目
每周股票复盘：浙江医药（600216）股东国投高科拟减持不超1%股份
证券之星 · 09-28
每周股票复盘：浙江医药（600216）股东国投高科拟减持不超1%股份
浙江医药：维生素E油是公司生命营养品板块的主导产品之一
证券日报 · 09-26
浙江医药：维生素E油是公司生命营养品板块的主导产品之一
浙江医药(600216.SH)：国投高科拟减持不超1%股份
智通财经 · 09-22
浙江医药(600216.SH)：国投高科拟减持不超1%股份
每周股票复盘：浙江医药（600216）Q2净利增28.46%，股东户数微增
证券之星 · 08-31
每周股票复盘：浙江医药（600216）Q2净利增28.46%，股东户数微增
股市必读：浙江医药中报 - 第二季度单季净利润同比增长28.46%
证券之星 · 08-27
股市必读：浙江医药中报 - 第二季度单季净利润同比增长28.46%
浙江医药(600216.SH)发布半年度业绩，归母净利润6.73亿元，同比增长113.52%
智通财经 · 08-25
浙江医药(600216.SH)发布半年度业绩，归母净利润6.73亿元，同比增长113.52%
浙江医药(600216)6月30日股东户数6.55万户，较上期增加0.55%
证券之星 · 08-25
浙江医药(600216)6月30日股东户数6.55万户，较上期增加0.55%
浙江医药最新公告：XC2309注射液获得药物临床试验批准通知书
证券之星 · 08-21
浙江医药最新公告：XC2309注射液获得药物临床试验批准通知书
浙江医药上周获融资净买入1613.40万元，居两市第494位
金融界 · 08-18
浙江医药上周获融资净买入1613.40万元，居两市第494位
暂无数据
公司概况
公司名称：
浙江医药股份有限公司
所属行业：
医药制造业
上市日期：
1999-10-21
主营业务：
浙江医药股份有限公司的主营业务是生命营养品、药品。公司的主要产品是合成维生素E、维生素A、天然维生素E、维生素H(生物素)、维生素D3、辅酶Q10、β-胡萝卜素、斑蝥黄素、叶黄素、番茄红素等维生素和类维生素产品、医药制造类产品及医药商业。报告期内，公司在CPHI2025荣获“LeadingEnterpriseofPharmaInternationalizationAwards”（医药国际化领军企业奖），在HHB健康美丽产业高质量发展大会被评为“健康美丽产业绿色可持续发展先锋企业”。
发行价格：
5.16
{"stockData":{"symbol":"600216","market":"SH","secType":"STK","nameCN":"浙江医药","latestPrice":13.68,"timestamp":1765954800000,"preClose":13.56,"halted":0,"volume":6151961,"delay":0,"changeRate":0.0088,"floatShares":961999999,"shares":961999999,"eps":1.2937,"marketStatus":"已收盘","change":0.12,"latestTime":"12-17 15:00:00","open":13.54,"high":13.74,"low":13.48,"amount":83822300,"amplitude":0.0192,"askPrice":13.68,"askSize":140,"bidPrice":13.67,"bidSize":364,"shortable":0,"etf":0,"ttmEps":1.2937,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766021400000},"marketStatusCode":5,"adr":0,"adjPreClose":13.56,"symbolType":"stock","openAndCloseTimeList":[[1765935000000,1765942200000],[1765947600000,1765954800000]],"highLimit":14.92,"lowLimit":12.2,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":961637750,"isCdr":false,"pbRate":1.19,"roa":"--","peRate":10.574322,"roe":"8.49%","epsLYR":1.21,"committee":-0.315814,"marketValue":13155000000,"turnoverRate":0.0064,"status":0,"floatMarketCap":13155000000},"requestUrl":"/m/hq/s/600216/tweets","defaultTab":"tweets","newsList":[{"id":"2586268215","title":"浙江医药（600216）发布向2025年限制性股票激励计划激励对象授予限制性股票公告，11月26日股价上涨0.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586268215","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586268215?lang=zh_cn&edition=full","pubTime":"2025-11-26 22:22","pubTimestamp":1764166946,"startTime":"0","endTime":"0","summary":"截至2025年11月26日收盘，浙江医药报收于14.03元，较前一交易日上涨0.14%，最新总市值为134.92亿元。该股当日开盘14.0元，最高14.22元，最低13.99元，成交额达1.02亿元，换手率为0.75%。近日，浙江医药发布公告称，公司已于2025年11月26日向875名激励对象授予1,028.4000万股限制性股票，授予价格为7.30元/股。授予条件已满足，限售期分别为12个月和24个月，分两期各解除限售50%。本次股权激励费用将在2025年至2027年摊销，预计总费用为6,921.13万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600038961.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0191","BK0028","600216","BK0188"],"gpt_icon":0},{"id":"2586625833","title":"浙江医药(600216.SH)筹划分拆控股子公司新码生物于香港联交所上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2586625833","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586625833?lang=zh_cn&edition=full","pubTime":"2025-11-26 17:51","pubTimestamp":1764150660,"startTime":"0","endTime":"0","summary":"智通财经APP讯，浙江医药(600216.SH)发布公告，为更好地促进公司药品生物制剂板块的发展，充分发挥资本市场优化资源配置的作用，拓宽融资渠道，从而提升公司整体的盈利能力和核心竞争力，公司拟筹划分拆控股子公司浙江新码生物医药有限公司(简称“新码生物”)于香港联合交易所有限公司(简称“香港联交所”)上市。本次分拆上市事项如若实施，不会导致公司丧失对新码生物的控制权，不会对公司其他业务板块的经营发展和公司整体的持续盈利能力造成重大不利影响，不会损害公司的独立上市地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373943.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"浙江医药(600216.SH)筹划分拆控股子公司新码生物于香港联交所上市","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0239","BK0028","BK0191","600216"],"gpt_icon":0},{"id":"2583659570","title":"每周股票复盘：浙江医药（600216）推1.07%股本激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2583659570","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583659570?lang=zh_cn&edition=full","pubTime":"2025-11-16 02:06","pubTimestamp":1763229977,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，浙江医药报收于14.86元，较上周的14.91元下跌0.34%。本周，浙江医药11月12日盘中最高价报15.12元。本周关注点公司公告汇总：浙江医药拟向875名激励对象授予不超过1,028.4000万股限制性股票，占公司股本总额的1.0694%。公司公告汇总：2025年第一次临时股东会审议通过限制性股票激励计划相关议案。公司对2025年限制性股票激励计划内幕信息知情人在2025年4月28日至10月27日期间的股票买卖情况进行了自查。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600216","BK0239","BK0028","BK0191","BK0188"],"gpt_icon":0},{"id":"2583599881","title":"浙江医药（600216）发布2025年限制性股票激励计划，11月13日股价上涨0.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583599881","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583599881?lang=zh_cn&edition=full","pubTime":"2025-11-13 22:26","pubTimestamp":1763043983,"startTime":"0","endTime":"0","summary":"截至2025年11月13日收盘，浙江医药报收于15.01元，较前一交易日上涨0.27%，最新总市值为144.34亿元。该股当日开盘15.03元，最高15.04元，最低14.9元，成交额达1.61亿元，换手率为1.12%。近日，浙江医药发布2025年限制性股票激励计划，拟向875名激励对象授予不超过1,028.4000万股限制性股票，占公司股本总额的1.0694%。本计划有效期不超过36个月，解除限售期分为两个阶段，分别在授予登记完成后的12个月和24个月后解除限售，解除限售比例均为50%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300042336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0239","BK0188","BK0028","600216"],"gpt_icon":0},{"id":"2582265869","title":"每周股票复盘：浙江医药（600216）拟授1028.4万股限制性股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2582265869","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582265869?lang=zh_cn&edition=full","pubTime":"2025-11-09 03:04","pubTimestamp":1762628655,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，浙江医药报收于14.91元，较上周的14.56元上涨2.4%。本周关注点公司公告汇总：浙江医药拟授予不超过1,028.4000万股限制性股票，占总股本1.0694%。公司公告汇总浙江医药股份有限公司拟实施2025年限制性股票激励计划，旨在健全长效激励机制，吸引和留住优秀人才，调动董事、高管及核心骨干积极性。浙江医药于2025年10月27日召开董事会审议通过2025年限制性股票激励计划（草案）及相关议案，并于10月28日在上交所网站披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","600216","BK0028","BK0188","BK0239"],"gpt_icon":0},{"id":"2581929889","title":"浙江医药（600216）披露2025年限制性股票激励计划激励对象名单公示结果，11月07日股价上涨1.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581929889","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581929889?lang=zh_cn&edition=full","pubTime":"2025-11-07 22:24","pubTimestamp":1762525465,"startTime":"0","endTime":"0","summary":"公司近日发布公告称，董事会薪酬与考核委员会对2025年限制性股票激励计划激励对象名单的公示情况进行了核查。浙江医药于2025年10月27日召开董事会，审议通过2025年限制性股票激励计划（草案）及相关议案，并于10月28日在上交所网站披露。公司随后在内部网站公示了本次激励计划的激励对象名单，公示期为2025年10月28日至11月6日，在此期间未收到任何异议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700039209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0028","600216","BK0188","BK0239"],"gpt_icon":0},{"id":"2581077514","title":"浙江医药（600216）披露拟实施2025年限制性股票激励计划，11月05日股价下跌0.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581077514","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581077514?lang=zh_cn&edition=full","pubTime":"2025-11-05 22:19","pubTimestamp":1762352362,"startTime":"0","endTime":"0","summary":"根据近日发布的公告，浙江医药股份有限公司拟实施2025年限制性股票激励计划，旨在健全长效激励机制，吸引和留住优秀人才，调动董事、高管及核心骨干积极性。相关议案包括《2025年限制性股票激励计划（草案）》及其摘要、《实施考核管理办法》及提请股东大会授权董事会办理激励计划相关事项。上述议案已于2025年10月27日经第十届董事会第八次会议审议通过，并于2025年11月13日提交临时股东大会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500040671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600216","BK0191","BK0028","BK0188"],"gpt_icon":0},{"id":"2580547671","title":"每周股票复盘：浙江医药（600216）Q3净利降51.37%，推1028.4万股激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2580547671","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580547671?lang=zh_cn&edition=full","pubTime":"2025-11-02 04:05","pubTimestamp":1762027517,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，浙江医药报收于14.56元，较上周的14.44元上涨0.83%。本周，浙江医药10月29日盘中最高价报14.89元。公司公告汇总：拟实施2025年限制性股票激励计划，授予1028.4万股，占总股本1.0694%。股本股东变化截至2025年9月30日，浙江医药股东户数为6.3万户，较6月30日减少2510户，减幅3.83%。业绩披露要点浙江医药2025年三季报显示，主营收入66.95亿元，同比下降5.87%；归母净利润9.33亿元，同比上升9.83%；扣非净利润8.91亿元，同比上升5.3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000735.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0028","600216","BK0239","BK0188"],"gpt_icon":0},{"id":"2578934220","title":"浙江医药（600216）披露2025年限制性股票激励计划（草案），10月28日股价上涨0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578934220","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578934220?lang=zh_cn&edition=full","pubTime":"2025-10-28 18:11","pubTimestamp":1761646277,"startTime":"0","endTime":"0","summary":"截至2025年10月28日收盘，浙江医药报收于14.5元，较前一交易日上涨0.49%，最新总市值为139.44亿元。该股当日开盘14.4元，最高14.59元，最低14.36元，成交额达2.09亿元，换手率为1.5%。同日，浙江医药发布《2025年限制性股票激励计划（草案）》，拟向875名激励对象授予不超过1,028.4000万股限制性股票，占公司股本总额的1.0694%，股票来源为二级市场回购。本计划有效期不超过36个月，限售期为12个月、24个月，分两期各解除限售50%。本计划经股东大会审议通过后实施。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800034207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0188","BK0028","600216","BK0239"],"gpt_icon":0},{"id":"2578622529","title":"图解浙江医药三季报：第三季度单季净利润同比下降51.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578622529","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578622529?lang=zh_cn&edition=full","pubTime":"2025-10-28 02:23","pubTimestamp":1761589389,"startTime":"0","endTime":"0","summary":"证券之星消息，浙江医药2025年三季报显示，公司主营收入66.95亿元，同比下降5.87%；归母净利润9.33亿元，同比上升9.83%；扣非净利润8.91亿元，同比上升5.3%；其中2025年第三季度，公司单季度主营收入23.72亿元，同比下降12.37%；单季度归母净利润2.6亿元，同比下降51.37%；单季度扣非净利润2.25亿元，同比下降57.41%；负债率20.69%，投资收益536.49万元，财务费用-9326.39万元，毛利率37.49%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800001999.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600216"],"gpt_icon":0},{"id":"2578683648","title":"浙江医药最新公告：拟投资16.85亿元建设昌北生物建设项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2578683648","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578683648?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:18","pubTimestamp":1761563927,"startTime":"0","endTime":"0","summary":"浙江医药(600216.SH)公告称，公司子公司昌北生物拟投资16.85亿元建设浙江医药昌北生物建设项目，项目分两期建设，旨在提升维生素等产品原辅料的自给能力，降低关键中间体对外的依存度。项目建成后，预计年销售额可达9亿元，毛利2.86亿元。本项目投资是基于公司发展战略和业务布局而作出的审慎决策，但未来经营效益的实现存在一定不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700029961.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0028","600216","BK0239","BK0188"],"gpt_icon":0},{"id":"2570891279","title":"每周股票复盘：浙江医药（600216）股东国投高科拟减持不超1%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2570891279","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570891279?lang=zh_cn&edition=full","pubTime":"2025-09-28 03:08","pubTimestamp":1759000095,"startTime":"0","endTime":"0","summary":"截至2025年9月26日收盘，浙江医药报收于14.25元，较上周的14.53元下跌1.93%。本周，浙江医药9月22日盘中最高价报14.67元。本周关注点公司公告汇总：持股5%以上股东国投高科计划减持不超过公司总股本1%的股份公司公告汇总浙江医药股份有限公司公告，持股5%以上股东国投高科技投资有限公司持有公司150,127,573股，占总股本15.61%。国投高科计划自公告披露之日起15个交易日后3个月内，通过集中竞价交易方式减持不超过9,616,377股，即不超过公司总股本的1%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092800000741.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0191","600216","BK0028"],"gpt_icon":0},{"id":"2570886072","title":"浙江医药：维生素E油是公司生命营养品板块的主导产品之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2570886072","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570886072?lang=zh_cn&edition=full","pubTime":"2025-09-26 20:10","pubTimestamp":1758888600,"startTime":"0","endTime":"0","summary":"证券日报网讯浙江医药9月26日在互动平台回答投资者提问时表示，维生素E油是公司生命营养品板块的主导产品之一，公司按照市场需求决定实际产量。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-26/doc-infrvstm6339572.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-26/doc-infrvstm6339572.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","BK0028","BK0191","600216","BK0239"],"gpt_icon":0},{"id":"2569882017","title":"浙江医药(600216.SH)：国投高科拟减持不超1%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2569882017","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569882017?lang=zh_cn&edition=full","pubTime":"2025-09-22 17:47","pubTimestamp":1758534435,"startTime":"0","endTime":"0","summary":"智通财经APP讯，浙江医药(600216.SH)发布公告，国投高科基于自身经营发展需要,计划于公告披露之日起15个交易日后的3个月内，通过集中竞价交易方式合计减持数量不超过961.64万股，即不超过公司总股本的1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1347977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","600216","BK0191","BK0239","BK0028"],"gpt_icon":0},{"id":"2563315538","title":"每周股票复盘：浙江医药（600216）Q2净利增28.46%，股东户数微增","url":"https://stock-news.laohu8.com/highlight/detail?id=2563315538","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563315538?lang=zh_cn&edition=full","pubTime":"2025-08-31 12:27","pubTimestamp":1756614432,"startTime":"0","endTime":"0","summary":"截至2025年8月29日收盘，浙江医药报收于15.66元，较上周的16.23元下跌3.51%。本周，浙江医药8月26日盘中最高价报16.45元。股本股东变化截至2025年6月30日，浙江医药股东户数为6.55万户，较3月31日增加358户，增幅0.55%。业绩披露要点浙江医药2025年中报显示，主营收入43.23亿元，同比下降1.87%；归母净利润6.73亿元，同比增长113.52%；扣非净利润6.65亿元，同比增长110.1%。公司公告汇总浙江医药第十届七次董事会于2025年8月25日以通讯方式召开，全体董事出席。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083100003987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0191","600216","BK0239"],"gpt_icon":0},{"id":"2562549756","title":"股市必读：浙江医药中报 - 第二季度单季净利润同比增长28.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562549756","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562549756?lang=zh_cn&edition=full","pubTime":"2025-08-27 01:23","pubTimestamp":1756228993,"startTime":"0","endTime":"0","summary":"业绩披露要点：浙江医药2025年中报显示，归母净利润6.73亿元，同比上升113.52%。公司公告汇总浙江医药2025年半年度报告摘要显示，总资产为14,201,909,522.50元，比上年度末增长2.95%。归属于上市公司股东的净利润为673,306,732.88元，比上年同期增长113.52%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082700001997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600216"],"gpt_icon":0},{"id":"2562223143","title":"浙江医药(600216.SH)发布半年度业绩，归母净利润6.73亿元，同比增长113.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562223143","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562223143?lang=zh_cn&edition=full","pubTime":"2025-08-25 23:09","pubTimestamp":1756134559,"startTime":"0","endTime":"0","summary":"智通财经APP讯，浙江医药(600216.SH)披露2025年半年度报告，报告期公司实现营收43.23亿元，同比下降1.87%;归母净利润6.73亿元，同比增长113.52%;扣非净利润6.65亿元，同比增长110.10%;基本每股收益0.70元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334927.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"浙江医药(600216.SH)发布半年度业绩，归母净利润6.73亿元，同比增长113.52%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600216"],"gpt_icon":0},{"id":"2562248654","title":"浙江医药(600216)6月30日股东户数6.55万户，较上期增加0.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562248654","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562248654?lang=zh_cn&edition=full","pubTime":"2025-08-25 18:17","pubTimestamp":1756117065,"startTime":"0","endTime":"0","summary":"证券之星消息，近日浙江医药披露，截至2025年6月30日公司股东户数为6.55万户，较3月31日增加358.0户，增幅为0.55%。在化学制药行业个股中，浙江医药股东户数高于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.27万户。从股价来看，2025年3月31日至2025年6月30日，浙江医药区间涨幅为10.21%，在此期间股东户数增加358.0户，增幅为0.55%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082500025633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0239","600216","BK0191"],"gpt_icon":0},{"id":"2561468821","title":"浙江医药最新公告：XC2309注射液获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2561468821","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561468821?lang=zh_cn&edition=full","pubTime":"2025-08-21 16:59","pubTimestamp":1755766777,"startTime":"0","endTime":"0","summary":"浙江医药(600216.SH)公告称，公司收到国家药品监督管理局核准签发关于XC2309注射液的《药物临床试验批准通知书》，同意开展临床试验。XC2309注射液是一种化学药品1类注射剂，规格为5ml:10mg，临床拟用于各种情况引起的消化道溃疡出血。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082100028041.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","600216","BK0028","BK0191"],"gpt_icon":0},{"id":"2560978695","title":"浙江医药上周获融资净买入1613.40万元，居两市第494位","url":"https://stock-news.laohu8.com/highlight/detail?id=2560978695","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560978695?lang=zh_cn&edition=full","pubTime":"2025-08-18 07:41","pubTimestamp":1755474076,"startTime":"0","endTime":"0","summary":"8月18日，沪深两融数据显示，浙江医药上周累计获融资净买入额1613.40万元，居两市第494位，上周融资买入额2.65亿元，偿还额2.49亿元。资金流方面，浙江医药近5日主力资金流出905.68万元，区间跌幅0.52%；近10日主力资金流出1.34亿元，区间跌幅3.43%。通过天眼查大数据分析，浙江医药股份有限公司共对外投资了28家企业，参与招投标项目83次，知识产权方面有商标信息190条，专利信息27条，此外企业还拥有行政许可46个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/18074152494425.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","BK0188","BK0191","BK0028","600216"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765990886557,"stockEarnings":[{"period":"1week","weight":-0.0172},{"period":"1month","weight":-0.0533},{"period":"3month","weight":-0.0719},{"period":"6month","weight":-0.0146},{"period":"1year","weight":-0.1231},{"period":"ytd","weight":-0.1165}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0256},{"period":"3month","weight":0.0101},{"period":"6month","weight":0.1519},{"period":"1year","weight":0.1514},{"period":"ytd","weight":0.1547}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"63021人(较上一季度减少3.83%)","perCapita":"15258股","listingDate":"1999-10-21","address":"浙江省绍兴市越城区滨海新城致远中大道168号","registeredCapital":"96163万元","survey":" 浙江医药股份有限公司的主营业务是生命营养品、药品。公司的主要产品是合成维生素E、维生素A、天然维生素E、维生素H(生物素)、维生素D3、辅酶Q10、β-胡萝卜素、斑蝥黄素、叶黄素、番茄红素等维生素和类维生素产品、医药制造类产品及医药商业。报告期内，公司在CPHI2025荣获“LeadingEnterpriseofPharmaInternationalizationAwards”（医药国际化领军企业奖），在HHB健康美丽产业高质量发展大会被评为“健康美丽产业绿色可持续发展先锋企业”。","listedPrice":5.16},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"浙江医药(600216)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供浙江医药(600216)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"浙江医药,600216,浙江医药股票,浙江医药股票老虎,浙江医药股票老虎国际,浙江医药行情,浙江医药股票行情,浙江医药股价,浙江医药股市,浙江医药股票价格,浙江医药股票交易,浙江医药股票购买,浙江医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"浙江医药(600216)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供浙江医药(600216)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}